ELTX Earnings — Elicio Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
ELTX — Elicio Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$12.28
Market Cap$219.3M
P/E—
52W Range$7.37 – $14.93
Next Earnings2026-08-06
About Elicio Therapeutics, Inc. Common Stock
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
